Evommune, Inc. $EVMN Shares Acquired by Stempoint Capital LP

Stempoint Capital LP lifted its holdings in shares of Evommune, Inc. (NYSE:EVMN) by 184.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 193,777 shares of the company’s stock after acquiring an additional 125,581 shares during the period. Stempoint Capital LP’s holdings in Evommune were worth $4,385,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Capricorn Fund Managers Ltd acquired a new position in Evommune during the 4th quarter valued at approximately $1,027,000. Sofinnova Investments Inc. purchased a new position in shares of Evommune in the fourth quarter worth $2,625,000. Seven Grand Managers LLC acquired a new stake in shares of Evommune during the fourth quarter worth $1,284,000. NEXTBio Capital Management LP acquired a new stake in shares of Evommune during the fourth quarter worth $3,908,000. Finally, EQT Fund Management S.a r.l. purchased a new stake in shares of Evommune during the fourth quarter valued at $84,395,000.

Evommune Price Performance

NYSE:EVMN opened at $11.04 on Thursday. The company’s fifty day moving average price is $17.48 and its 200-day moving average price is $21.54. Evommune, Inc. has a 1-year low of $10.47 and a 1-year high of $33.20. The firm has a market capitalization of $397.67 million and a P/E ratio of -1.16.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. Equities analysts anticipate that Evommune, Inc. will post -2.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EVMN. William Blair lowered Evommune from an “outperform” rating to a “market perform” rating in a research note on Monday, June 29th. Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Stifel Nicolaus assumed coverage on Evommune in a report on Friday, May 1st. They issued a “buy” rating and a $54.00 price objective on the stock. Weiss Ratings cut Evommune from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Finally, HC Wainwright downgraded Evommune from a “buy” rating to a “neutral” rating in a report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.62.

Insider Activity at Evommune

In other news, CEO Luis C. Pena sold 7,438 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $22.71, for a total value of $168,916.98. Following the sale, the chief executive officer owned 630,458 shares in the company, valued at $14,317,701.18. This represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeegar Pravinkumar Patel sold 1,488 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $22.50, for a total value of $33,480.00. Following the sale, the insider directly owned 46,403 shares in the company, valued at approximately $1,044,067.50. This trade represents a 3.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 100,854 shares of company stock worth $2,279,142 in the last three months. Company insiders own 31.10% of the company’s stock.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.